A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aviragen Therapeutics
- 21 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2017.
- 04 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment, according to an Aviragen Therapeutics media release, .
- 02 Feb 2017 According to an Aviragen Therapeutics media release, company plans to initiate this trial in Q1 2017.